Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$51.41 -3.7%	$48.19	$21.02 ▼ $58.40	$4.25B	-0.15	1.05 million shs	1.42 million shs
ELVN Enliven Therapeutics	$19.65 -2.0%	$19.43	$13.30 ▼ $30.03	$984.33M	0.83	292,015 shs	884,482 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
MRUS Merus	$52.66 +0.1%	$49.26	$33.19 ▼ $62.98	$3.64B	1	739,511 shs	583,213 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-3.65%	-4.66%	+0.76%	+22.55%	+121.98%
ELVN Enliven Therapeutics	-2.04%	-7.14%	+10.15%	-1.06%	-13.44%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+4.41%
MRUS Merus	+0.11%	-2.72%	-5.44%	+22.44%	-3.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.5707 of 5 stars	3.5	1.0	0.0	4.7	2.0	0.8	0.0
ELVN Enliven Therapeutics	2.2738 of 5 stars	3.5	0.0	0.0	0.0	2.6	4.2	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	1.8027 of 5 stars	3.6	1.0	0.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	60.47% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	101.53% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
MRUS Merus	3.14	Buy	$84.64	60.72% Upside

Current Analyst Ratings Breakdown

Latest ELVN, AKRO, MRUS, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/9/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$83.00 ➝ $83.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
MRUS Merus	$36.13M	100.87	N/A	N/A	$9.46 per share	5.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)

Latest ELVN, AKRO, MRUS, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
ELVN Enliven Therapeutics	N/A	21.07	21.06
MOR MorphoSys	4.98	1.38	1.38
MRUS Merus	N/A	5.86	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
ELVN Enliven Therapeutics	95.08%
MOR MorphoSys	18.38%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
ELVN Enliven Therapeutics	25.90%
MOR MorphoSys	0.05%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable

ELVN, AKRO, MRUS, and MOR Headlines

Recent News About These Companies

Merus N.V.: Making Progress

June 29 at 8:54 AM | seekingalpha.com

Merus N.V. (MRUS) Latest Stock News & Headlines - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Stocks Showing Rising Market Leadership: Merus Earns 81 RS Rating

June 25, 2025 | msn.com

Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock

June 25, 2025 | insidertrades.com

Peter B. Silverman Sells 34,000 Shares of Merus N.V. (NASDAQ:MRUS) Stock

June 24, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Net Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)

June 14, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Has $2.71 Million Stake in Merus (NASDAQ:MRUS)

June 12, 2025 | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11, 2025 | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | insidermonkey.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Bank of America Corp DE Has $1.59 Million Stock Position in Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Shares Gap Down - What's Next?

June 4, 2025 | marketbeat.com

Merus Shares Slide on Stock Offering

June 4, 2025 | marketwatch.com

Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares

June 3, 2025 | quiverquant.comQ

Merus N.V. Announces Pricing of Public Offering of Common Shares

June 3, 2025 | globenewswire.com

Merus NV Announces Proposed Public Offering of Common Shares | MRUS stock news

June 3, 2025 | gurufocus.com

Merus N.V. Announces Proposed Public Offering of Common Shares

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN, AKRO, MRUS, and MOR Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$51.41 -1.95 (-3.65%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$51.88 +0.47 (+0.90%)

As of 07/1/2025 07:55 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Enliven Therapeutics NASDAQ:ELVN

$19.65 -0.41 (-2.04%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$19.65 0.00 (0.00%)

As of 04:00 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 06/30/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Merus NASDAQ:MRUS

$52.66 +0.06 (+0.11%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$52.60 -0.06 (-0.12%)

As of 07/1/2025 04:15 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time